6,8-Disubstituted-9-(heterocyclyl)purines for use in pharmaceutical and cosmetic compositions and applications are provided. These 6,8-disubstituted-9-(heterocyclyl)purines have a wide range of biological activities, including for example antioxidant, anti-inflammatory, anti-senescent, anti-aging, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. Compositions may include additional excipients and auxiliary substances. Methods of treatment of animals, mammals, plants, cells, yeast, and cells in tissue culture are also disclosed.

The present disclosure relates to luterion, which is a mitochondrial-like micro-material, and separating and culturing methods for same and, more particularly, to a method for separating luterion by means of a filter having a pore of a particular size, luterion which is separated by means of the method thereof and has unique properties, and a culturing method for proliferation of the luterion.

The present disclosure relates to luterion, which is a mitochondrial-like micro-material, and separating and culturing methods for same and, more particularly, to a method for separating luterion by means of a filter having a pore of a particular size, luterion which is separated by means of the method thereof and has unique properties, and a culturing method for proliferation of the luterion.

The present disclosure relates to a Taraxacum Coreanum phytoplacenta cell culture extract that has moisturizing and soothing effects for extremely dry skin such as atopic dermatitis, and skin barrier strengthening effect. The Taraxacum Coreanum phytoplacenta cell culture or an extract thereof according to the present disclosure is non-toxic to skin cells, and has an efficacy of moisturizing, anti-aging, strengthening the skin barrier, improving wrinkles, soothing the skin, protecting the skin from UV rays, and protecting the skin from blue light, etc.

The present disclosure relates to a Taraxacum Coreanum phytoplacenta cell culture extract that has moisturizing and soothing effects for extremely dry skin such as atopic dermatitis, and skin barrier strengthening effect. The Taraxacum Coreanum phytoplacenta cell culture or an extract thereof according to the present disclosure is non-toxic to skin cells, and has an efficacy of moisturizing, anti-aging, strengthening the skin barrier, improving wrinkles, soothing the skin, protecting the skin from UV rays, and protecting the skin from blue light, etc.

The invention refers to standardized plant extract from biomass of in vitro cultures of Haberlea rhodopensis Friv. (HR), containing bioactive compounds and their primary secondary metabolites, containing in weight %, as follows: organic acid from 4.0 to 6.0, fatty acids from 0.5 to 1.5, amino acids from 8.0 to 12.0, sterols from 0.5 to 1.0, free phenols from 3.0 to 6.0, sugars from 45 to 55, and polyphenols from 25.0 to 35.0, with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract, and to a composition containing the standardized extract and glycerol as well as to a method for the preparation of a standardized plant extract.

The method according this invention, along with its optimally chosen steps, specific conditions, parameters such as temperature, duration, stirring, light, growth factors, etc. achieves both maximum volumetric productivity of the target substances and myconoside, as well as stable productivity of the plant in vitro cultures and is a reliable efficient 24/7 continuous system for production of NPs.

Dependence on natural factors, limited availability and protection of HR rare wild plant populations are eliminated. The limitations posed by seasonality and slow HR growth are also avoided by developing a renewable, ecologically method. The developed method provides alternative, renewable and sustainable sources of raw plant material necessary to obtain the target extract. The resulting extract standardized in myconoside is especially valuable with its protective action on human health and can successfully be used with its pharmacological, cosmetic effects as well as in functional foods.

The invention refers to standardized plant extract from biomass of in vitro cultures of Haberlea rhodopensis Friv. (HR), containing bioactive compounds and their primary secondary metabolites, containing in weight %, as follows: organic acid from 4.0 to 6.0, fatty acids from 0.5 to 1.5, amino acids from 8.0 to 12.0, sterols from 0.5 to 1.0, free phenols from 3.0 to 6.0, sugars from 45 to 55, and polyphenols from 25.0 to 35.0, with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract, and to a composition containing the standardized extract and glycerol as well as to a method for the preparation of a standardized plant extract.

The method according this invention, along with its optimally chosen steps, specific conditions, parameters such as temperature, duration, stirring, light, growth factors, etc. achieves both maximum volumetric productivity of the target substances and myconoside, as well as stable productivity of the plant in vitro cultures and is a reliable efficient 24/7 continuous system for production of NPs.

Dependence on natural factors, limited availability and protection of HR rare wild plant populations are eliminated. The limitations posed by seasonality and slow HR growth are also avoided by developing a renewable, ecologically method. The developed method provides alternative, renewable and sustainable sources of raw plant material necessary to obtain the target extract. The resulting extract standardized in myconoside is especially valuable with its protective action on human health and can successfully be used with its pharmacological, cosmetic effects as well as in functional foods.

Described herein are methods, compositions, and systems for production of saline tolerant plants. In some cases, such plants are produced by genome editing.

Described herein are methods, compositions, and systems for production of saline tolerant plants. In some cases, such plants are produced by genome editing.

The present invention relates to a lysosomal protein composition comprising a plurality of lysosomal proteins that are potentially diversely glycosylated according to a glycosylation pattern, wherein said glycosylation pattern has at least 45% paucimannosidic N-glycans; a method of manufacturing the lysosomal protein composition in a bryophyte plant or cell, and medical and non-medical uses of the lysosomal protein composition. E.g. the lysosomal protein can be α-Galactosidase for the treatment of Fabry Disease or β-Glucoceramidase for the treatment of Gaucher's Disease. The unique glycosylation results in improved therapeutic efficacy—surprisingly even without mannose-6-phosphate that is common for CHO cell produced lysosomal proteins.